Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.

Journal: Journal of pediatric gastroenterology and nutrition

PMID: 38374555

BACKGROUND: Infliximab (IFX) use is limited by loss of response often due to the development of anti-IFX antibodies and low drug levels.

Naamah Zitomersky

Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA.
Lisa Chi

Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA.
Enju Liu

Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts, USA.
Kurtis R Bray

Prometheus Laboratories Inc, San Diego, California, USA.
Konstantinos Papamichael

Harvard Medical School, Boston, Massachusetts, USA.
Adam S Cheifetz

Harvard Medical School, Boston, Massachusetts, USA.
Scott B Snapper

Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA.
Athos Bousvaros

Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA.
Jocelyn A Silvester

Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA.

Adolescent Antibodies Child Colitis, Ulcerative Crohn Disease Drug Monitoring Female Gastrointestinal Agents Humans Immunologic Factors Inflammatory Bowel Diseases Infliximab Prospective Studies Young Adult

View on PubMed Access via DOI PubMed (38374555)